Spinovit developed a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction. This technology provides a precise assessment of vascular health, addressing the need for reliable diagnostics in cardiovascular disease management.
Funding
$570K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
There is a need for precise assessment of vascular health, particularly in the context of cardiovascular disease management. Existing methods for measuring endothelial dysfunction may lack the quantitative rigor required for reliable diagnostics.
Solution
Spinovit developed a method for the quantitative analysis of an oxygen-sensitive blood biomarker. This technology aimed to provide a precise assessment of vascular health, addressing the need for reliable diagnostics in cardiovascular disease management. The company's approach focused on quantifying endothelial dysfunction through the analysis of specific biomarkers in blood samples. This quantitative assessment was intended to offer clinicians a more accurate and reliable tool for evaluating vascular health and making informed treatment decisions.
Target Audience
The primary target audience included clinicians and researchers involved in cardiovascular disease management, seeking more precise and reliable diagnostic tools for assessing vascular health.
Features
- Quantitative analysis of oxygen-sensitive blood biomarker
- Assessment of endothelial dysfunction
- Diagnostic tool for cardiovascular disease management